Blogged on behalf of Natalia Forero Serna
Dr Thomas Fuerst, Executive Vice President, Chief Scientific Officer, PharmAthene presented today at the World Vaccine Congress Lyon to give details on the development of a robust manufacturing platform for production of a next generation anthrax vaccine. The production of this vaccine will be achieved through the use of modern vaccine production technologies for the manufacture of SparVaxâ„¢, the well characterized recombinant Protective Antigen (rPA) anthrax vaccine, the established a robust manufacturing platform at full commercial scale and a comprehensive set of analytical assays for in process, release, and stability testing.
SparVaxâ„¢, a highly purified recombinant version of a protective antigen, is currently in the 1st and 2nd clinical trials, already completed with more than 770 individuals. The target of this vaccine is for military and civilian use.
To put us all into context, Dr. Fuerst gave us an overview of the mechanism of action of anthrax disease, so how edema and necrosis are caused by a very complex interaction and cascades of proteins, he also mentioned the complex characteristics of the protective antigen structure.
You might be asking yourself, what is the real progress of this attractive vaccine? The vaccine is well tolerated, antibody levels are similar to protective levels in animals, the product is stable, it has protection against different conditions (such as aerosol), and it has been analyzed via extensive assays such as: Imaging capillary electrophoresis, LDS page, chromatograms, fluorescence spectroscopy, among others. Concerning the strain production, is highly standardized with improvements in the productivity and linear scale process.
To conclude, the next generation anthrax vaccine has a significant efficacy and safety, the technologies involved in the development are successful, it is controlled, produced at high concentrations, and tested by good analytic assays.
The presentations from the event will be made available from the 1st November.